URGN UroGen Pharma Ltd.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1668243 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY159.3%
TTM net income YoY60.1%
TTM EPS YoY—
Revenue 3-yr CAGR47.9%
Net income 3-yr CAGR—
Margins
Gross margin91.4%
Operating margin-12.4%
Net margin-26.3%
FCF margin-52.8%
EBITDA margin-12.2%
Returns
ROE—
ROA-28.8%
ROIC (approx.)—
Asset turnover1.10x
Leverage & solvency
Liabilities / assets146.1%
Debt / equity—
Current ratio3.40x
Interest coverage—
Cash quality & payout
Operating cash flow / net income2.01x
Accruals ratio28.9%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $109.79M | $90.40M | $82.71M | $64.36M | $48.04M |
| Cost of revenue | $12.45M | $8.88M | $9.36M | $7.65M | $5.16M |
| Gross profit | $97.34M | $81.52M | $73.35M | $56.70M | $42.88M |
| R&D expense | $67.11M | $57.15M | $45.61M | $52.91M | $47.64M |
| SG&A expense | $155.10M | $121.15M | $93.27M | $82.84M | $87.53M |
| Operating income | -$124.86M | -$96.78M | -$65.54M | -$79.04M | -$92.29M |
| Pretax income | -$153.42M | -$124.04M | -$98.32M | -$108.03M | -$109.37M |
| Income tax | $78,000 | $2.83M | $3.92M | $1.75M | $1.45M |
| Net income | -$153.49M | -$126.87M | -$102.24M | -$109.78M | -$110.82M |
| EBITDA | -$124.56M | -$96.45M | -$64.73M | -$78.12M | -$91.46M |
| EPS (basic) | -3.19 | -2.96 | -3.55 | -4.81 | -4.96 |
| EPS (diluted) | — | — | — | — | -4.96 |
| Weighted avg. shares (diluted) | — | — | — | — | 22.35M |
| Balance sheet | |||||
| Cash & equivalents | $110.75M | $171.99M | $95.00M | $55.41M | $44.36M |
| Short-term investments | $9.71M | $110.67M | $56.16M | $44.56M | $44.78M |
| Receivables | $33.08M | $20.30M | $15.44M | $12.70M | $11.72M |
| Inventory | $16.46M | $9.23M | $5.67M | $4.33M | $4.83M |
| Current assets | $186.02M | $276.13M | $169.19M | $128.91M | $114.39M |
| PP&E, net | $637,000 | $655,000 | $689,000 | $1.30M | $1.97M |
| Total assets | $200.46M | $285.71M | $178.31M | $135.62M | $119.75M |
| Current liabilities | $46.42M | $45.95M | $31.21M | $23.92M | $22.38M |
| Long-term debt | $122.21M | $121.73M | $98.55M | $97.54M | $0 |
| Total debt | $122.21M | $121.73M | $98.55M | $97.54M | $0 |
| Total liabilities | $305.93M | $294.51M | $243.52M | $224.98M | $111.33M |
| Shareholders' equity | -$105.47M | -$8.80M | -$65.21M | -$89.36M | $8.41M |
| Net debt | $11.46M | -$50.25M | $3.55M | $42.13M | -$44.36M |
| Shares outstanding | 48.35M | 42.23M | 32.49M | 23.13M | 22.46M |
| Cash flow statement | |||||
| Operating cash flow | -$162.44M | -$96.77M | -$76.38M | -$87.56M | -$84.89M |
| Capital expenditure | $289,000 | $295,000 | $194,000 | $254,000 | $752,000 |
| Free cash flow | -$162.73M | -$97.06M | -$76.57M | -$87.81M | -$85.64M |
| Investing cash flow | $61.56M | -$20.61M | -$953,000 | $1.06M | $4.07M |
| Financing cash flow | $39.92M | $194.62M | $116.93M | $97.13M | $72.32M |
| Depreciation & amortization | $307,000 | $329,000 | $802,000 | $924,000 | $831,000 |
| Stock-based compensation | $11.96M | $13.11M | $9.34M | $10.58M | $23.11M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.